MPC Therapeutics logo — Making cell therapies more durable and effective through met...

MPC Therapeutics

Making cell therapies more durable and effective through metabolic reprograming.

Founded 2018 Switzerland Plan-les-ouates, Switzerland 8 employees Debt Financing Total: $2.66M Biotechnology, Health Care

General Information

Company Name MPC Therapeutics
Founded Year 2018
Location Switzerland Plan-les-ouates, Switzerland
Founders / Decision Makers
Team member
Employees 8
Industries Biotechnology, Health Care
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with MPC Therapeutics. To contact MPC Therapeutics, visit mpc-therapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MPC Therapeutics compare?

A PDF of MPC Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MPC Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MPC Therapeutics

MPC Therapeutics is a biotech company focused on cellular rejuvenation to combat cancer and degenerative pathologies. Headquartered in Switzerland and founded in 2018, the startup is harnessing the potential of mitochondria as therapeutic targets. Their innovative approach involves proprietary first-in-class small molecules that specifically target mitochondria to induce metabolic reprogramming. MPC Therapeutics aims to enhance the efficacy of cell therapies and address degenerative pathologies through their pioneering techniques. The company recently received a Fr.100.00K debt financing investment on 16 November 2023 from the FONGIT Innovation Fund. This infusion of capital underscores the confidence of investors in MPC Therapeutics' vision and technology. As MPC Therapeutics continues to make strides in the biotechnology and healthcare sectors, their commitment to leveraging mitochondria for cellular rejuvenation holds great promise in the fight against cancer and degenerative diseases. For more information, visit their website.

Business keywords: Biotech, Cellular Rejuvenation, Mitochondria, Metabolic Reprogramming, Cell Therapies, Cancer Treatment, Degenerative Pathologies, Small Molecules, Therapeutic Targets, Switzerland, Startup, Healthcare Innovation

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing Fr.100.00K 1
FONGIT Innovation Fund
16 Nov 2023
Seed Round Fr.1.50M 1
Plutus Investment Group
10 Jan 2023
Grant $180.00K -
01 Nov 2020
Grant Fr.650.00K 1
Innosuisse
01 Jul 2019
Grant Fr.10.00K 1
KICK Ventures
04 Jun 2019
Convertible Note Fr.220.00K 1
Eclosion SA
01 Apr 2019

MPC Therapeutics Alternatives & Competitors

View All Alternatives
MPC Therapeutics vs

Pioneering novel therapies to address cancer and metabolic disorders by targeting essential cellular...

Debt Financing
Biotechnology, Health Care
MPC Therapeutics vs
Celularity Inc.
Celularity Inc. United States

A next-gen Biotech company creating off-the-shelf cellular medicines for Cancer, Infectious, and Deg...

Post-IPO Equity
171 employees
Biotechnology, Health Care
MPC Therapeutics vs

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology

FAQ About MPC Therapeutics

Making cell therapies more durable and effective through metabolic reprograming.
MPC Therapeutics was founded in 2018.
MPC Therapeutics is headquartered in Plan-les-ouates, Switzerland.
MPC Therapeutics operates in Biotechnology and Health Care. Its work centres on Biotech, Cellular Rejuvenation, Mitochondria and Metabolic Reprogramming.
MPC Therapeutics has approximately 8 employees.
MPC Therapeutics has completed 6 funding rounds, raising a total of $2.66M. The latest funding stage is Debt Financing.
Top alternatives and competitors to MPC Therapeutics include Petra Pharma, Celularity Inc., Prescient Therapeutics, Eterna Therapeutics, (주)온코인사이트 / OncoInsight Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MPC Therapeutics and Petra Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MPC Therapeutics, https://bouncewatch.com/company/mpc-therapeutics, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes